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It would be a considerable advantage to be able to identify
women at high risk for developing breast cancer to justify
closer follow-up and use of multiple methods to ensure
early detection. At present, the only high risk individuals
identifiable with a biomarker are those 5% with a strong
familial history of breast cancer. For the remaining 95%
there is a lack of such biomarkers. Three independent epi-
demiologic studies found that women with mammary
epithelial cells (MEC) in their nipple aspirate fluids (NAF)
were more likely to subsequently develop breast cancer
than women without cells. A possible explanation for this
is that early stages of breast carcinogenesis and tumor pro-
gression most likely involve MEC hyperplasia triggered by
a carcinogenic agent. Viruses cause several major human
cancers (e.g. primary liver cancer and cervical cancer).
Recent studies found bovine leukemia virus (BLV),
Epstein-Barr virus (EBV), and human papilloma virus
(HPV) more frequently in breast tissues of women with
breast cancer vs. those with no breast cancer history.
The objective in this study is to determine if oncogenic
viruses in NAF MEC can serve as biomarkers to identify
women at high risk for breast cancer. Specific aims are 1)
to test the feasibility of detecting genomes of BLV, EBV,
and HPV in MEC from NAF using in situ PCR, which
allows localization of the signal to individual cells; 2) to
determine if viral presence in NAF correlates with viral
presence in matching breast tissue from the same donor;
3) to determine if viruses are present more frequently in
women with breast cancer history than those without. The
pilot grant from the Dr. Susan Love Research Foundation
has enabled us to tackle some of the technical challenges
(specific aim #1). The first challenge was to minimize loss
of NAF MEC from the slide during the PCR reaction. We
found that neither modifications of fixation nor addition
of viscous additives could improve adherence when NAF
cells were sparse. Therefore, we will use only samples with
at least 100 cells per slide to assure adherence of enough
cells to analyze. The second challenge is to screen for 3
viruses using one NAF preparation per donor, since that is
all that is available to us. We have worked out a scheme
whereby all three viruses could be amplified simultane-
ously and then detected individually with specific DNA
probes in one in situ hybridization reaction. Each probe
would have a different label incorporated into its DNA,
with the final detection signal fluorescing at different
wavelengths. We have begun to test this triple label system
using three control cell lines each harboring one of the
three viruses.
Specific aims #2 and #3 involve analysis of patient sam-
ples for the presence of the three oncogenic viruses. With
co-funding from the Avon Foundation, we have begun the
acquisition of matching tissue sections and NAF (cyt-
ospun onto slides) from the same donor, provided by Drs.
Krishnamurthy and Kuerer at M.D. Anderson Cancer
Center in Houston, TX. Women with NAF cell abnormal-
ities are 4–5 times more likely to develop breast cancer
than women with no NAF. This pilot study aims to deter-
mine if that risk is related to oncogenic viruses and to eval-
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uate the feasibility of detecting these viruses in NAF. The
results could be translational, enabling identification of
women at higher risk of developing breast cancer, just as
HPV screening of cervical samples is now being used.Page 2 of 2
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